Yan Xing, M.D., Ph.D.

800-826-4673
Yan Xing, M.D., Ph.D.
Medical Oncologist
Clinical Expertise
  • Solid Tumors
  • Skin Cancer
  • Phase I Clinical Trials
  • Melanoma
Research Area
  • Immunotherapy
Other Languages Spoken
Cantonese
Mandarin
Academic Appointments
  • Assistant Professor, Department of Medical Oncology & Therapeutics Research
Clinical Teams
Medical Oncology & Therapeutics Research
Skin Cancer and Melanoma
Thyroid Cancer
Research Teams
Developmental Cancer Therapeutics Program (CCC)
As a physician, the goal of Yan Xing, M.D., Ph.D., is simple: to be there for her patients and their families “when they need it most.”
 
As an accomplished researcher, Dr. Xing goes further. She strives to improve cancer treatment and outcomes through rigorous data analyses to better determine which practices work best. She is also passionate about the potential of personalized medicine and new drug development, which she calls “essential to maximize the treatment outcome of cancer patients.”
 
Educated in China, Dr. Xing earned her medical degree at Sun Yat-Sen University of Medical Sciences. Upon her arrival in the U.S. she received a Ph.D. in biostatistics from University of Texas School of Public Health. Continuing her medical training, Dr. Xing completed a fellowship in medical oncology at Houston Methodist Hospital, as well as a fellowship in Phase I clinical trials at MD Andersen Cancer Center.
 
Dr. Xing is delighted to be part of City of Hope's family. She appreciates the steadfast support given to the staff, and she admires the unmatched level of compassionate patient care.
 

Location

Education & Experience

Board Certifications

  • 2017, Diplomate, American Board of Oncology

Degrees

  • 2008, Ph.D., Biostatistics, School of Public Health, University of Texas, Houston, TX

  • 2003, M.S., Health Informatics, School of Health Information Sciences, University of Texas, Houston, TX

Fellowship

  • 2017-2018, Phase I Clinical Trials, MD Anderson Cancer Center, Houston, TX

  • 2015-2017, Medical Oncology, Houston Methodist Hospital, Houston, TX

Residency

  • 2012-2015, Internal Medicine, Mount Auburn Hospital, Cambridge, MA

Professional Experience

  • 2018-present, Assistant Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA

  • 2008-2012, Assistant Professor, Department of Surgical Oncology - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

  • 2008-2012, Assistant Professor, Division of Management, Policy and Community Health, The University of Texas School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX

Publications

  • Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93:539-46, 2006. 
  • Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 2009. 
  • Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 116(11):2234-2241, 2010. 
  • Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, Royal R, Cormier JN. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients. Journal of the National Cancer Institute. 103:1-14, 2011. 
  • Chagpar R, Xing Y, Chiang YJ, Feig BW, Chang GJ, You YN, Cormier JN. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol. 30(9):972-9. 03/2012. 
  • Massarweh N, Chiang YJ, Xing Y, Chang GJ, Haynes A, You YN, Feig BW, Cormier JN. Association between travel distance and metastatic disease at diagnosis among patients with colon cancer. J Clin Oncol. 3/20/2014; 32(9):942-8. PMID: 24516014. 
  • Xing Y, Zhang J, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN Jr. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer 02/2016; 122(4):534-45. PMID: 26554754 
  • Yan Xing, Nancy U Lin, Matthew A Maurer, Huiqin Chen, Armeen Mahvash, Aysegul Sahin, Argun Akcakanat, Yisheng Li, Vandana Abramson, Jennifer Litton, Mariana Chavez-MacGregor, Vicente Valero, Sarina A Piha-Paul, David Hong, Kim-Anh Do, Emily Tarco, Dianna Riall, Agda Karina Eterovic, Gerburg M Wulf, Lewis C Cantley, Gordon B Mills, L Austin Doyle, Eric Winer, Gabriel N Hortobagyi, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam.  Phase II Trial of AKT Inhibitor MK-2206 in Patients With Advanced Breast Cancer Who Have Tumors With PIK3CA or AKT Mutations, and/or PTEN loss/PTEN Mutation. Breast Cancer Res., 2019 Jul 5;21(1):78 
  • Villalona-Calero MA, Malhotra J, Chung V, Xing Y, Gray SW, Hampel H, Gruber S, McDonnell K. Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience. J Clin Med. 2023 Jun 15;12(12):4061. doi: 10.3390/jcm12124061.PMID: 37373756 
  • Zhang T, Jou TH, Hsin J, Wang Z, Huang K, Ye J, Yin H, Xing Y. Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy. J Clin Med. 2023 Jan 31;12(3):1098. doi: 10.3390/jcm12031098. PMID: 36769745 

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
4.8
Show respect for what you say
4.7
Provider listen carefully to you
4.7
Know important info medical history
4.7
Spend enough time with you
4.6
Recommend this provider office
4.6
Provider explain in way you understand
4.6
Rate provider 0-10
06/15/24
Terrible bedside manner, lack of empathy, saw her about 5 minutes for each visit. She did not thoroughly go over test results from each or prior visits. - Verified patient
06/10/24
Excellent experience - Verified patient
04/23/24
Very impressive. Knows her stuff. I'm confident in her advice. - Verified patient
03/06/24
Dr Xing is proactive and thorough. I really appreciate her level of care. - Verified patient
03/06/24
COH is the best!! - Verified patient